Curanex Pharmaceuticals Inc CURX
4.70 USD +0.07 (+1.40%)
Regular-session close
4.59 -0.11 -2.34%
After hours · Nov 17, 4:00 PM ET
4.70 Day range 5.23
3.58 52-week range 13.34
- YTD
- -29.00%
- 1 year
- -54.72%
News
prnewswire.com Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) NEW YORK, May 22, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc.…
prnewswire.com Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) NEW YORK, May 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc.…
globenewswire.com Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious…
prnewswire.com Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) NEW YORK, May 12, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc.…
globenewswire.com CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Curanex…
businesswire.com Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc.…
businesswire.com Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc.…
globenewswire.com Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease
globenewswire.com Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets
defenseworld.net Head to Head Review: Curanex Pharmaceuticals (NASDAQ:CURX) and Zomedica (OTCMKTS:ZOMDF) Curanex Pharmaceuticals (NASDAQ: CURX - Get Free Report) and Zomedica (OTCMKTS:ZOMDF - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast…
globenewswire.com Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)…
feeds.benzinga.com EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.
globenewswire.com Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform
globenewswire.com Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18,…
globenewswire.com Curanex Expands Scientific Advisory Board With Two Distinguished Researchers New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy
globenewswire.com Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq:…
globenewswire.com Curanex Forms World Class Scientific Advisory Board Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX)…
feeds.benzinga.com What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compliant batch supporting its planned IND submission for ulcerative colitis.
globenewswire.com Curanex Provides Operational Update on Key Regulatory Milestones Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”…
globenewswire.com Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and…
